TCGA-91-6829-01A-21R-1858-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- TGF_BETA_SIGNALING+0.460
- UV_RESPONSE_DN+0.460
- PROTEIN_SECRETION+0.430
- MITOTIC_SPINDLE+0.340
- ANDROGEN_RESPONSE+0.250
- APICAL_JUNCTION+0.210
- G2M_CHECKPOINT+0.150
- MYOGENESIS+0.150
- ANGIOGENESIS+0.130
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.370
- MYC_TARGETS_V2-0.360
- IL6_JAK_STAT3_SIGNALING-0.310
- ALLOGRAFT_REJECTION-0.300
- P53_PATHWAY-0.280
- OXIDATIVE_PHOSPHORYLATION-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- KRAS_SIGNALING_DN-0.250
- ESTROGEN_RESPONSE_LATE-0.230
- INFLAMMATORY_RESPONSE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A24L-01A-11R-A169-07 | — | B | 0.814 |
| 2 | TCGA-DQ-5631-01A-01R-1873-07 | — | — | 0.804 |
| 3 | TCGA-AR-A24M-01A-11R-A169-07 | — | B | 0.803 |
| 4 | TCGA-A8-A097-01A-11R-A034-07 | — | C | 0.776 |
| 5 | TCGA-A8-A09A-01A-11R-A00Z-07 | — | B | 0.770 |
| 6 | TCGA-AN-A041-01A-11R-A034-07 | — | B | 0.765 |
| 7 | TCGA-AO-A0JA-01A-11R-A056-07 | — | A | 0.755 |
| 8 | 5b6bd2fd-de8e-4d58-9b38-c3b2bf2ed418 | — | — | 0.752 |
| 9 | TCGA-B6-A0WT-01A-11R-A109-07 | — | B | 0.746 |
| 10 | TCGA-ZF-AA4R-01A-11R-A38B-07 | — | — | 0.737 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |